ClinicalTrials.gg
CompletedNCT01353859Updated Jun 6, 2014Results posted

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 5 sites in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
84th of 110
39 · median 97
Started
2011
with 13 others
Phase 3
65 of 110
none open now
Registered
54th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 84th largest by enrollment, is one of 14 that started in 2011, is one of 65 in phase 3, and was the 54th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multicenter, open-label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with active rheumatoid arthritis who have an inadequate response to non-biologic disease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for a total of 6 infusions plus methotrexate 10-25 mg orally weekly. Anticipated time on study treatment is 24 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Moderate to severe active rheumatoid arthritis (RA) of >/= 6 months duration
  • Prior treatment with DMARDs for >/= 12 weeks (at stable dose for >/= 8 weeks)
  • Inadequate clinical response to stable dose of non-biologic DMARD (either single or in combination)

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment
  • disease other than RA
  • History of or current inflammatory joint disease other than RA
  • Previous treatment with any biologic drug that is used in the treatment of RA
  • Intra-articular or parenteral within 6 weeks prior to baseline
  • Impaired liver, renal or hematologic function
  • Active current or history of recurrent infection
  • History of or currently active primary or secondary immunodeficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: tocilizumab [RoActemra/Actemra] · Drug: methotrexate

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg iv every 4 weeks for a total of 6 infusions

  • 10-25 mg orally weekly

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Low Disease Activity Score

    Disease Activity Score using 28-Joint Count (DAS28) was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog scale \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

    Time frame: Week 24

Secondary outcomes

  1. Time to Achieve Low Disease Activity (DAS28 ≤3.2)

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity; time to low disease activity was calculated as the time in weeks from the date of first infusion to the first achievement of DAS28 ≤3.2

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24

  2. Percentage of Participants With a Clinically Significant Improvement in DAS28 Score

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement in DAS28 score was defined as a reduction of at least 1.2 units.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  3. Time to Clinically Significant Improvement in DAS28

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement is a reduction in DAS28 score of at least 1.2 units. Time to clinically significant improvement was determined in weeks from the date of first infusion to the date of first achievement of reduction of 1.2 units in DAS28.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  4. Percentage of Participants Achieving DAS28 Remission (DAS28 <2.6)

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Remission was defined as DAS28 \<2.6.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24

  5. Time to Achieve DAS28 Remission (DAS28 <2.6)

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 remission was defined as DAS28 \<2.6. Time to achieve remission was calculated in weeks as the time from the date of first infusion to the date of first achieving remission.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  6. Percentage of Participants With DAS28 <3.2 by Visit

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24

  7. Percentage of Participants Achieving American College of Rheumatology (ACR) 20%, 50%, and 70% Improvement (ACR20, ACR50, or ACR70) Response

    ACR20/50/70 response was defined as ≥20%, ≥50%, or ≥70% improvement, respectively, in swollen/tender joint count (66 joints assessed for swelling and 68 joints assessed for tenderness) as well as improvement in at least 3 of the 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the health assessment questionnaire \[HAQ\]); and acute phase response: C-reactive protein (CRP) or ESR.

    Time frame: Week 24

  8. Erythrocyte Sedimentation Rate

    Erythrocyte Sedimentation rate was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  9. C-Reactive Protein Levels

    CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.

    Time frame: Baseline, Weeks 4, 8, 12,16, 20, and 24

07

Results

Posted Jun 6, 2014

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab + Methotrexate (MTX)
Started39
Completed35
Not completed4
Withdrew: Adverse event3
Withdrew: Lack of efficacy1

Outcome measures

PrimaryPercentage of Participants Achieving Low Disease Activity Score

Disease Activity Score using 28-Joint Count (DAS28) was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog scale \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity Score
percentage of participantsTocilizumab + MTX
Percentage of Participants Achieving Low Disease Activity Score100
SecondaryTime to Achieve Low Disease Activity (DAS28 ≤3.2)

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity; time to low disease activity was calculated as the time in weeks from the date of first infusion to the first achievement of DAS28 ≤3.2

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · weeks
Time to Achieve Low Disease Activity (DAS28 ≤3.2)
weeksTocilizumab + MTX
Time to Achieve Low Disease Activity (DAS28 ≤3.2)9.5 ± 5.3
SecondaryPercentage of Participants With a Clinically Significant Improvement in DAS28 Score

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement in DAS28 score was defined as a reduction of at least 1.2 units.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Significant Improvement in DAS28 Score
percentage of participantsTocilizumab + MTX
Week 487.2
Week 891.9
Week 1294.7
Week 1697.3
Week 2097.3
Week 24100
SecondaryTime to Clinically Significant Improvement in DAS28

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement is a reduction in DAS28 score of at least 1.2 units. Time to clinically significant improvement was determined in weeks from the date of first infusion to the date of first achievement of reduction of 1.2 units in DAS28.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · weeks
Time to Clinically Significant Improvement in DAS28
weeksTocilizumab + MTX
Time to Clinically Significant Improvement in DAS2812.5 ± 6.3
SecondaryPercentage of Participants Achieving DAS28 Remission (DAS28 <2.6)

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Remission was defined as DAS28 \<2.6.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DAS28 Remission (DAS28 <2.6)
percentage of participantsTocilizumab + MTX
Baseline0.0
Week 420.5
Week 836.8
Week 1244.7
Week 1659.0
Week 2074.4
Week 2482.1
SecondaryTime to Achieve DAS28 Remission (DAS28 <2.6)

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 remission was defined as DAS28 \<2.6. Time to achieve remission was calculated in weeks as the time from the date of first infusion to the date of first achieving remission.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · weeks
Time to Achieve DAS28 Remission (DAS28 <2.6)
weeksTocilizumab + MTX
Time to Achieve DAS28 Remission (DAS28 <2.6)4.4 ± 1.6
SecondaryPercentage of Participants With DAS28 <3.2 by Visit

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28 <3.2 by Visit
percentage of participantsTocilizumab + MTX
Baseline0.0
Week 430.8
Week 848.7
Week 1269.2
Week 1682.1
Week 2089.7
Week 24100
SecondaryPercentage of Participants Achieving American College of Rheumatology (ACR) 20%, 50%, and 70% Improvement (ACR20, ACR50, or ACR70) Response

ACR20/50/70 response was defined as ≥20%, ≥50%, or ≥70% improvement, respectively, in swollen/tender joint count (66 joints assessed for swelling and 68 joints assessed for tenderness) as well as improvement in at least 3 of the 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the health assessment questionnaire \[HAQ\]); and acute phase response: C-reactive protein (CRP) or ESR.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology (ACR) 20%, 50%, and 70% Improvement (ACR20, ACR50, or ACR70) Response
percentage of participantsTocilizumab + MTX
ACR2020
ACR5034
ACR7034
SecondaryErythrocyte Sedimentation Rate

Erythrocyte Sedimentation rate was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate
mm/hrTocilizumab + MTX
Baseline48.1 ± 26.1
Week 410.7 ± 13.5
Week 89.1 ± 10.5
Week 126.3 ± 4.3
Week 168.3 ± 8.3
Week 206.6 ± 4.3
Week 245.8 ± 3.3
SecondaryC-Reactive Protein Levels

CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.

Time frame:
Baseline, Weeks 4, 8, 12,16, 20, and 24
Reported as:
Mean · mg/L
C-Reactive Protein Levels
mg/LTocilizumab + MTX
Baseline17.6 ± 21.6
Week 42.1 ± 8.5
Week 80.8 ± 1.9
Week 120.5 ± 1.0
Week 161.2 ± 4.4
Week 201.0 ± 2.6
Week 240.4 ± 0.3

Adverse events

Collected over Adverse events were recorded from the day of baseline evaluation until the end of study at Week 24.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab + MTX—2/39 (5.1%)37/39 (94.9%)
Most frequent serious events
Most frequent serious events
EventTocilizumab + MTX
SepsisInfections and infestations1/39
Pulmonary tuberculosisInfections and infestations1/39
Most frequent other events
Showing 10 of 50
Most frequent other events
EventTocilizumab + MTX
Hepatic enzyme increasedInvestigations12/39
HypercholesterolaemiaMetabolism and nutrition disorders9/39
ArthralgiaMusculoskeletal and connective tissue disorders8/39
Pain in extremityMusculoskeletal and connective tissue disorders6/39
StomatitisGastrointestinal disorders5/39
Pain ankleMusculoskeletal and connective tissue disorders5/39
DyspepsiaGastrointestinal disorders3/39
CoughRespiratory, thoracic and mediastinal disorders3/39
InfluenzaRespiratory, thoracic and mediastinal disorders3/39
HeadacheNervous system disorders3/39

Baseline characteristics

Intent to treat (ITT) population: all participants included in the study who received at least one dose of study medication. Participants prematurely withdrawn from the study will be considered as nonresponders at the end of the study in all analyses of treatment response variables.

Age, Continuous
Age, Continuous(years)Tocilizumab + MTX
Median53 (19 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab + MTX
Female36
Male3
08

Study locations

5 sites
  • Bandung, 40161, Indonesia
  • Central Jakarta, 10430, Indonesia
  • East Java, Indonesia
  • Malang, 65111, Indonesia
  • Yogyakarta, 55284, Indonesia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2011
First posted
May 16, 2011
Start
Mar 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Jun 6, 2014
Last update
Jun 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01353859
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 16, 2011
Start date
Mar 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Jun 6, 2014
Last update
Jun 6, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Methotrexate

Start the discussion